Estimated reading time: 6 minutes
The American Cancer Society (ACS) is now recommending routine prostate cancer screening for men in specific age and risk groups, marking a significant shift from its previous emphasis on shared decision-making.
Released November 12, the updated guidelines are the organization’s first revision since 2010. They recommend prostate-specific antigen (PSA) blood testing every two years for average-risk men ages 50 to 69, with annual screening beginning at age 45 for Black men and men with a strong family history of prostate cancer.
The recommendations also define how to evaluate elevated PSA levels, including repeat testing, MRI and biomarkers to help determine whether a biopsy is necessary.
For nurses in primary care, urology, oncology and community health, these changes provide clearer guidance for identifying patients at increased risk, discussing screening options and supporting follow-up care.
What Changed in the Prostate Cancer Screening Guidelines?
Under its 2010 guidelines, the ACS encouraged men to discuss the benefits and risks of PSA screening with their healthcare providers before deciding whether to undergo testing.
The new recommendations go further by directly recommending regular screening for specific populations, reflecting stronger evidence that PSA testing can reduce prostate cancer deaths and advanced disease.
Shared decision-making remains important, with clinicians expected to explain the benefits, limitations and potential harms before screening begins.
Mina M. Fam, MD, MBA, medical director of urologic oncology at Hackensack Meridian Jersey Shore University Medical Center and medical director of robotic surgery at Hackensack Meridian Ocean University Medical Center, says the changes provide patients with clearer direction.
“The newly updated American Cancer Society guidelines are a massive step forward for patient empowerment. For years, the recommendation was simply to ‘have a conversation’ with your doctor, which often left men in the dark. Now, patients have a concrete game plan. If you are at average risk, you should be getting a PSA blood test every two years between the ages of 50 and 69. If you are high-risk – specifically if you are a Black man or have a strong family history of the disease – you need to start getting screened annually at age 45,” says Fam.
Who Should Be Screened and When?
The updated ACS recommendations establish different screening schedules based on age, race and family history:
- Average-risk men ages 50 to 69: PSA screening every two years.
- Black men ages 45 to 69: Annual PSA screening.
- Non-Black men with a strong family history: Annual screening from ages 45 to 69. This includes men with a first-degree relative diagnosed before age 65 or multiple first-degree relatives diagnosed at any age.
- Non-Black men with one first-degree relative diagnosed at age 65 or older: Screening every two years from ages 45 to 69.
- Men ages 70 to 74: Individualized decisions about continuing screening based on overall health, life expectancy and personal preferences.
- Men ages 75 and older: Screening is generally not recommended, although exceptionally healthy men ages 75 to 79 may discuss continued testing with their healthcare providers.
Screening is not recommended for men with a life expectancy of less than 10 years.
Elevated PSA? New Guidelines Emphasize Testing Before Biopsy
One of the most clinically significant changes involves how clinicians evaluate an elevated PSA result.
For men ages 45 to 69, a PSA level of 3.0 ng/mL or higher warrants further evaluation. For men ages 70 to 74, the threshold is 6.5 ng/mL or higher.
Rather than proceeding directly to biopsy, the ACS recommends repeating an elevated PSA test within two weeks to three months. If the result remains elevated, MRI and/or validated biomarker testing should be offered to help determine whether a biopsy is necessary.
An elevated PSA does not automatically indicate prostate cancer. The additional testing is meant to identify clinically significant cancers while reducing unnecessary invasive procedures.
For nurses, understanding this diagnostic pathway can help address patient concerns about abnormal results and explain why additional evaluation may be necessary.
Want to see more Nurse Approved articles in your Google results? Add us as a preferred source.
Add Nurse Approved as apreferred source on Google
“My advice to patients is to be proactive at your next annual checkup,” shares Fam. “Don’t wait for your doctor to bring it up; instead, ask them directly: ‘Given my age, race, and family history, where do I fall in the new prostate cancer screening guidelines?’ One of the biggest fears men have about screening is the risk of an unnecessary and painful biopsy. The beauty of this guideline update is that it officially recommends secondary testing – like an MRI or a biomarker test – if your initial PSA is elevated. This means screening is now smarter and safer than ever, allowing us to find dangerous cancers early enough to cure them, while sparing men from unnecessary overtreatment.”
Active Surveillance Recommended for Low-Risk Prostate Cancer
The updated guidelines also address overtreatment by recommending active surveillance as the initial management option for men diagnosed with low-risk prostate cancer. This approach involves monitoring the disease rather than immediately beginning treatment, allowing clinicians to identify changes that may warrant intervention.
For oncology and urology nurses, the recommendation reinforces the importance of helping patients understand their diagnosis, treatment options and the need for continued monitoring.
Earlier Screening Aims to Address Prostate Cancer Disparities
Black men are 67% more likely to be diagnosed with prostate cancer than white men and face nearly twice the mortality rate, according to the ACS.
The updated recommendation for annual screening beginning at age 45 is intended to improve early detection among men at increased risk.
For nurses involved in preventive care and community outreach, recognizing these disparities can help inform conversations about screening and encourage appropriate follow-up.
More Than 333,000 Prostate Cancer Diagnoses Expected in 2026
Prostate cancer is the most commonly diagnosed cancer among men in the United States, excluding skin cancer, and the second-leading cause of cancer death in men.
The ACS estimates that 333,830 men will be diagnosed with prostate cancer in 2026, and 36,320 will die from the disease.
Although prostate cancer can be deadly, survival rates are substantially higher when the disease is diagnosed before it spreads.
The National Cancer Institute reports an overall five-year relative survival rate of 98.2% for prostate cancer. According to the ACS, the rate exceeds 99% when cancer is detected before spreading beyond the prostate gland.
The statistics highlight the importance of identifying potentially dangerous cancers earlier while avoiding unnecessary testing and treatment.
What the New Guidelines Mean for Nurses
Understanding the revised screening ages and intervals can help nurses identify patients who may benefit from discussions about PSA testing, particularly those with a family history of prostate cancer or other risk factors.
Nurses can also help patients understand that an elevated PSA result does not necessarily mean cancer and that additional testing may be needed before a biopsy is considered.
For patients diagnosed with low-risk prostate cancer, education about active surveillance can help address concerns about delaying immediate treatment and reinforce the importance of ongoing follow-up.
Fam encourages patients to take an active role in their preventive care.
“Don’t let fear or embarrassment keep you from prioritizing your health,” he adds. “Routine screenings are simple, highly individualized, and life-saving.”
For nurses, the updated guidelines reinforce the importance of individualized risk assessment, informed screening discussions and appropriate follow-up, particularly for patients at increased risk of prostate cancer.
